{"id":"W4397007282","doi":"10.1016/j.esmoop.2024.103202","title":"180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Centre Hospitalier Universitaire Vaudois","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Oncology; Chemotherapy; Breast cancer; Internal medicine; Radiology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001408749,0.001698829,0.002092976,0.0002911971,0.0003808536,0.001000047,0.0009401861,0.001394264,0.0155245],"category_scores_gemma":[0.001106917,0.0008819989,0.0009903772,0.0002958166,0.0009253544,0.0006548945,0.0005291089,0.002877054,0.002411356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008505216,"about_ca_system_score_gemma":0.001643959,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007415557,"about_ca_topic_score_gemma":0.002737913,"domain_scores_codex":[0.9996004,0.0001810089,0.00001976255,0.00008042406,0.00003398446,0.00008453243],"domain_scores_gemma":[0.9995831,0.00006984511,0.00007715336,0.0000477503,0.00003200512,0.0001901945],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9667705,0.008212373,0.0003303957,0.0004214729,0.0002184105,0.00001855181,0.00003505506,0.0002663037,0.007386831,0.0002546455,0.002673477,0.01341192],"study_design_scores_gemma":[0.9304716,0.06497265,0.0007450824,0.00002418744,0.0001178217,0.00002297616,0.0000073352,0.0003234338,0.0006709612,0.0001569694,0.002477456,0.000009514124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9308825,0.00269394,0.002246852,0.001020858,0.001376376,0.03872744,0.008447609,0.00063685,0.01396764],"genre_scores_gemma":[0.9230502,0.001969873,0.005244497,0.002272757,0.0006566246,0.03534464,0.007745899,0.000139123,0.02357646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0155245,"threshold_uncertainty_score":0.05193466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05708297713041971,"score_gpt":0.4125401569395417,"score_spread":0.355457179809122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}